RT Journal Article
SR Electronic
T1 Contaminating manufacturing plasmids and disrupted vector genomes present in liver tissue following adeno-associated virus gene therapy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2025.01.13.25320105
DO 10.1101/2025.01.13.25320105
A1 Buddle, Sarah
A1 Brown, Li-An K
A1 Morfopoulou, Sofia
A1 Torres Montaguth, Oscar Enrique
A1 Scoto, Mariacristina
A1 Herder, Vanessa
A1 Dhawan, Anil
A1 Brown, Julianne R
A1 Atkinson, Laura
A1 Kopec, Angelika
A1 Davis, Dee
A1 Storey, Nathaniel
A1 Campos, Luis
A1 Sebire, Neil
A1 Macpherson, Hannah
A1 Lee, Jasmaine
A1 Orton, Richard
A1 Baranello, Giovanni
A1 Asamaphan, Patawee
A1 Ilia, Georgios
A1 Karda, Rajvinder
A1 Belfield, Holly
A1 ISARIC 4C Investigators
A1 Semple, Malcolm Gracie
A1 Baillie, J Kenneth
A1 Counsell, John
A1 Waddington, Simon
A1 Thomson, Emma C
A1 Muntoni, Francesco
A1 Breuer, Judith
YR 2025
UL http://medrxiv.org/content/early/2025/01/14/2025.01.13.25320105.abstract
AB Adeno-associated viruses (AAVs) are the most used vectors in gene therapy but can frequently cause liver complications in patients. The mechanisms underlying AAV-related liver toxicity remain poorly understood, posing challenges for effective prevention and intervention. We undertook long and short read metagenomic sequencing of liver tissue from a child with spinal muscular atrophy type 1 experiencing significant hepatitis after receiving onasemnogene abeparvovec. We identified manufacturing plasmid sequences, with evidence of complex structures and recombination. Vector genomes had extensive disruption and concatemerisation. We also identified the presence of human betaherpesvirus 6B in the liver. It is possible that presence of the manufacturing plasmid sequences or helper viruses allow replication of the vector within cells, contributing to the development of complex concatemeric structures and associated hepatitis.Competing Interest StatementGB is PI of clinical trials Sponsored by Roche, Novartis, Sarepta, Pfizer, NS Pharma, Reveragen, Percheron, Biomarin, Scholar Rock, and has received speaker and/or consulting fees from Sarepta, PTC Therapeutics, Entrada Therapeutics, Pfizer, Biogen, Novartis Gene Therapies, Inc. (AveXis), and Roche, and grants from Sarepta, Roche and Novartis Gene Therapies. UCL has received funding from Sarepta, Roche, Pfizer, Italfarmaco, Santhera. FM is the PI of the Novartis sponsored trials in which OA was studied in the UK, and is also involved in clinical trials sponsored by Biogen, Roche, Sarepta Therapeutics, Genethon, PTC therapeutics and Solid Bioscience. He has received consulting fees from Pfizer, Sarepta, Roche, Biogen, Novartis, Solid, Dyne Therapeutics, Entrada, PTC and Edgewise. MS is the sub-I of the Novartis sponsored trials in which OA was studied in the UK, and is also involved in clinical trials sponsored by Biogen, Roche, Dyne. She has received consulting fees from Roche, Biogen and Novartis.Funding StatementSB, OMT and SM are funded by the National Institute for Health Research (NIHR) Blood and Transplant Research Unit for Genomics to Enhance Microbiology Screening (NIHR203338). LB is funded by the NIHR Great Ormond Street Biomedical Research Centre (BRC). JB receives funding from the NIHR UCL/UCLH BRC. JB is an NIHR Senior Investigator. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. RK is funded by LifeArc P2020-0008 and P2023-0011, Great Ormond Street Hospital Children Charity and Dravet Syndrome UK Charity V4720 and V4919 and Therapeutic Acceleration Support (TAS), UCL. This work was supported by grants CRUSH MC_UU_00034/9 and Wellcome Trust 226141/Z/22/Z. The support of the GOSH and UCLH/ Institute of Neurology BRC to the Dubowitz Neuromuscular Centre Biobank is gratefully acknowledged.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Residual diagnostic material was analysed with informed consent for additional research under the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) WHO Clinical Characterisation Protocol UK (CCP-UK) (ISRCTN 66726260). The South Central-Oxford Research Ethics Committee in England (13/SC/0149), the Scotland A Research Ethics Committee (20/SS/0028) and the WHO Ethics Review Committee (RPC571 and RPC572) gave ethical approval for the ISARIC CCP-UK study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData produced in the present study are available upon reasonable request to the authors.